Can average-risk medulloblastoma adult patients be treated with radiotherapy and plus chemotherapy?

2022 Background: The standard treatment in children with average-risk medulloblastoma (MB) is chemotherapy after reduced-dose radiotherapy (23.4 Gy of craniospinal irradiation and a posterior fossa boost to 55.8 Gy). However, in adults, there is no agreement on the use of adjuvant chemotherapy in this setting. Methods: We performed a retrospective analysis of adult MB pts with average-risk disease, defined as no postsurgical residual (or 16 years, post-surgical treatment with standard craniospinal irradiation with or without adjuvant chemotherapy (cisplatin and etoposide ± cyclophosphamide). Results: From 1988 to 2012 were accrued 43 average-risk MB pts treated with surgery and adjuvant radiotherapy. Fifteen (34.9%) pts received also chemotherapy: 7 before radiotherapy (RT), 5 after RT, and 3 before and after RT. Median age was 31 years (range: 16-57), M/F ratio 27 (62.8%)/16 (37.2%). Histology was classic in 24 pts (55.8%), des...